Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC1123 (ICV) in Pediatric Patients with MPS II
NCT05422482Phase 1Active, not recruiting
- Sponsor
- GC Biopharma Corp
- Start
- Sep 2022
- Primary completion
- Jun 2027
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Idursulfase beta in mucopolysaccharidosis type II, sponsored by GC Biopharma Corp. Primary endpoints: Incidence and frequency of serious adverse events (SAEs), Frequency and characteristics of adverse events and 1 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
Idursulfase beta
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT05422482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422482.